Jeffrey Stein - 27 Mar 2023 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: President & CEO, Director
Signature: /s/ Shane Ward, Attorney-in-Fact
Issuer symbol: CDTX
Transactions as of: 27 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 29 Mar 2023, 17:30:23 UTC
Previous filing: 23 Feb 2023
Next filing: 09 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDTX	Common Stock	Award	$0	+271,750	+29%	$0.000000	1,202,385	27 Mar 2023	Direct	F1, F2
holding	CDTX	Common Stock						281,602	27 Mar 2023	By trust
holding	CDTX	Common Stock						42,009	27 Mar 2023	By son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDTX	Employee Stock Option (right to buy)	Award	$0	+543,500		$0.000000	543,500	27 Mar 2023	Common Stock	543,500	$1.01	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents time-based Restricted Stock Units (RSUs) granted on March 27, 2023. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2024, 2025, and 2026, subject to continuous service through each such vesting date.
F2	Includes 8,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on May 20, 2022 and November 18, 2022.
F3	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023.